Neothetics Provides Update and Plan Forward for LIPO-202 Program
SAN DIEGO, March 28, 2016 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) today provided an update and plan forward for its LIPO-202 program. Neothetics plans to initiate a Phase 2 trial with a modified formulation of LIPO-202 in the third quarter of …